Literature DB >> 16945746

Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.

Paul Knaapen1, Willem G van Dockum, Marco J W Götte, Kimiko A Broeze, Joost P A Kuijer, Jaco J M Zwanenburg, J Tim Marcus, Wouter E M Kok, Albert C van Rossum, Adriaan A Lammertsma, Frans C Visser.   

Abstract

BACKGROUND: Regional differences in resting myocardial blood flow (MBF) have been observed in patients with hypertrophic cardiomyopathy (HCM), but their determinants are currently unknown. This study verifies whether MBF at rest in HCM is related to delayed contrast enhancement (DCE) or regional systolic function (or both) as determined by magnetic resonance imaging. METHODS AND
RESULTS: Fourteen patients with HCM were studied. MBF was measured with positron emission tomography by use of oxygen 15-labeled water. DCE and tissue tagging, to calculate end-systolic circumferential shortening (Ecc), were obtained with magnetic resonance imaging. The mean resting MBF was 0.78 +/- 0.19 mL x min(-1) x mL(-1), and there was a trend toward reduced MBF in the septum (0.72 +/- 0.11 mL x min(-1) x mL(-1)) compared with that in the lateral wall (0.84 +/- 0.29 mL x min(-1) x mL(-1)) (P = .092). The distribution patterns of DCE and Ecc were both heterogeneous, displaying significantly increased enhancement and impaired regional systolic function in the hypertrophic septum compared with the lateral wall (both P < .001). Resting MBF was inversely related to the extent of DCE (r = -0.30, P < .001), whereas MBF was not significantly related to Ecc (r = -0.15, P = .072).
CONCLUSIONS: Regional heterogeneity of resting perfusion in HCM is related to the extent of DCE but not to regional systolic function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16945746     DOI: 10.1016/j.nuclcard.2006.05.018

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  34 in total

1.  Pathophysiology of chronic left ventricular dysfunction. New insights from the measurement of absolute myocardial blood flow and glucose utilization.

Authors:  N V Marinho; B E Keogh; D C Costa; A A Lammerstma; P J Ell; P G Camici
Journal:  Circulation       Date:  1996-02-15       Impact factor: 29.690

2.  Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy.

Authors:  M Grover-McKay; M Schwaiger; J Krivokapich; J K Perloff; M E Phelps; H R Schelbert
Journal:  J Am Coll Cardiol       Date:  1989-02       Impact factor: 24.094

3.  Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  Willem G van Dockum; Aernout M Beek; Folkert J ten Cate; Jurrien M ten Berg; Olga Bondarenko; Marco J W Götte; Jos W R Twisk; Mark B M Hofman; Cees A Visser; Albert C van Rossum
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

4.  Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET.

Authors:  P A Kaufmann; T Gnecchi-Ruscone; J T Yap; O Rimoldi; P G Camici
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

5.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease.

Authors:  A M Varnava; P M Elliott; S Sharma; W J McKenna; M J Davies
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

6.  Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction.

Authors:  J Czernin; G Porenta; R Brunken; J Krivokapich; K Chen; R Bennett; A Hage; C Fung; J Tillisch; M E Phelps
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

7.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  Human heart: tagging with MR imaging--a method for noninvasive assessment of myocardial motion.

Authors:  E A Zerhouni; D M Parish; W J Rogers; A Yang; E P Shapiro
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

9.  Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols.

Authors:  F Hermansen; S D Rosen; F Fath-Ordoubadi; J S Kooner; J C Clark; P G Camici; A A Lammertsma
Journal:  Eur J Nucl Med       Date:  1998-07

10.  Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy.

Authors:  Paul Knaapen; Ronald Boellaard; Marco J W Götte; Pieter A Dijkmans; Linda M C van Campen; Carel C de Cock; Gert Luurtsema; Cees A Visser; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

View more
  9 in total

1.  Heterogeneity of intramural function in hypertrophic cardiomyopathy: mechanistic insights from MRI late gadolinium enhancement and high-resolution displacement encoding with stimulated echoes strain maps.

Authors:  Anthony H Aletras; Gauri S Tilak; Li-Yueh Hsu; Andrew E Arai
Journal:  Circ Cardiovasc Imaging       Date:  2011-05-16       Impact factor: 7.792

2.  Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy.

Authors:  Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

Review 3.  Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Martin S Maron
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-01       Impact factor: 5.364

Review 4.  The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance.

Authors:  Radwa A Noureldin; Songtao Liu; Marcelo S Nacif; Daniel P Judge; Marc K Halushka; Theodore P Abraham; Carolyn Ho; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2012-02-20       Impact factor: 5.364

5.  Cardiovascular magnetic resonance T2* mapping for structural alterations in hypertrophic cardiomyopathy.

Authors:  Mareike Gastl; Alexander Gotschy; Jochen von Spiczak; Malgorzata Polacin; Florian Bönner; Christiane Gruner; Malte Kelm; Frank Ruschitzka; Hatem Alkadhi; Sebastian Kozerke; Robert Manka
Journal:  Eur J Radiol Open       Date:  2019-02-04

6.  Cardiac magnetic resonance T2 mapping and feature tracking in athlete's heart and HCM.

Authors:  Mareike Gastl; Vera Lachmann; Aikaterini Christidi; Nico Janzarik; Verena Veulemans; Sebastian Haberkorn; Leonie Holzbach; Christoph Jacoby; Bernhard Schnackenburg; Susanne Berrisch-Rahmel; Tobias Zeus; Malte Kelm; Florian Bönner
Journal:  Eur Radiol       Date:  2020-10-15       Impact factor: 5.315

Review 7.  The Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Hypertrophic Cardiomyopathy.

Authors:  Sanjay Sivalokanathan
Journal:  Diagnostics (Basel)       Date:  2022-01-26

Review 8.  Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance.

Authors:  Marco Francone
Journal:  ISRN Radiol       Date:  2014-02-04

9.  Coronary microvascular ischemia in hypertrophic cardiomyopathy - a pixel-wise quantitative cardiovascular magnetic resonance perfusion study.

Authors:  Tevfik F Ismail; Li-Yueh Hsu; Anders M Greve; Carla Gonçalves; Andrew Jabbour; Ankur Gulati; Benjamin Hewins; Niraj Mistry; Ricardo Wage; Michael Roughton; Pedro F Ferreira; Peter Gatehouse; David Firmin; Rory O'Hanlon; Dudley J Pennell; Sanjay K Prasad; Andrew E Arai
Journal:  J Cardiovasc Magn Reson       Date:  2014-08-12       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.